However, the possibility of blocking the activation of the sTWEAK-Fn14 system (anti-sTWEAK or anti-Fn14 monoclonal antibodies, or through sTWEAK-Fn14 fusion blockade) makes this marker a hopeful therapeutic target that could decrease the progression of LA and stroke recurrence (48, 49). The gene discussed is TNFRSF12A; the disease is Stroke.